This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Celldex Therapeutics, Inc.
Drug Names(s): CR002
Description: CR002 is a fully human monoclonal antibody, generated with Abgenix's XenoMouse(R) technology, which neutralizes PDGF-D, a mediator discovered by CuraGen that stimulates mesangial cell proliferation. Mesangial cell proliferation has been implicated in the pathogenesis of IgA nephropathy, lupus nephritis, and diabetic nephropathy, forms of kidney inflammation that can lead to kidney failure.
Deal Structure: CR002 was originally developed by CuraGen.
In May 2009, Celldex Therapeutics announced it entered into a definitive agreement to acquire CuraGen. In October 2009, Celldex Therapeutics announced the successful completion of its acquisition of CuraGen Corporation.
Partners: Amgen, Inc.
Additional information available to subscribers only: